Esole Delayed Release Granules contain Esomeprazole 10 mg, a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. Esomeprazole works by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. This delayed-release formulation ensures that the active ingredient is released in the intestine, protecting it from degradation by gastric acid and enhancing bioavailability. Esole Delayed Release Granules are suitable for patients who have difficulty swallowing tablets and can be administered orally by mixing with water or soft food. The 10 mg dose is typically used for mild acid-related disorders or as part of a step-down therapy after higher doses. Clinical studies have demonstrated that Esomeprazole effectively reduces gastric acidity, promotes healing of erosive esophagitis, and alleviates symptoms such as heartburn and regurgitation. Common adverse effects include headache, diarrhea, and abdominal discomfort, which are generally mild and transient. Esole Delayed Release Granules should be used under medical supervision, with attention to contraindications such as hypersensitivity to proton pump inhibitors. Regular monitoring is recommended during prolonged therapy to assess therapeutic response and detect potential side effects.